OncoBone Therapeutics is pleased to announce nominating Dr. Gergana Galabova as VP Translational Research from August 1, 2025. Dr. Galabova has strong experience in designing and performing IND-enabling studies for preclinical therapeutic assets.
OncoBone Therapeutics develops novel therapies for cancer bone metastasis to IND-ready stage and finds outlicensing partners for clinical development. Dr. Galabova will be responsible for the development of three novel therapeutic assets recently added in our pipeline, a small-molecule inhibitor OTX-001, an antibody-drug conjugate OTX-002, and a radiopharmaceutical OTX-003.
Dr. Tiina Kähkönen, CSO of OncoBone Therapeutics said: “We are delighted to have Gergana join our Team. Her experience in translational research, IND-enabling and early clinical studies is extremely valuable for us and complements perfectly the skills of our Team.”
Dr. Galabova added, “I am excited for the opportunity to work in OncoBone Therapeutics. I am impressed about their ambitious Team and their determined efforts in developing novel therapies for cancer patients with bone metastases, who currently have no effective therapies available.”